Am Fam Physician. 2023;108(4):420-422
Author disclosure: No relevant financial relationships.
Published online September 18, 2023.
Key Points for Practice
• One dose of nirsevimab is recommended for infants up to eight months of age born during or entering their first RSV season, and for children between eight and 19 months of age who remain vulnerable to severe RSV disease through their second RSV season.
• A single-dose RSV vaccine can be offered to adults 60 years and older after shared decision-making.
• The influenza vaccine is recommended for all people older than six months, with no additional safety measures for egg allergies because there is minimal risk of a reaction.
• All children should receive either the 20- or 15-valent PCV between two and 23 months of age.
From the AFP Editors
In the United States, respiratory syncytial virus (RSV) infection causes seasonal epidemics of respiratory illness, leading to severe symptoms, lower respiratory tract disease, hospitalization, and death in infants and older adults. RSV infection is one of the most common causes of childhood illness, and it is the most common cause of hospitalization in infants, with up to 80,000 hospitalizations and 300 deaths occurring annually in children younger than five years.
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
